RG+A was engaged by a global device manufacturer to position an innovative device for in-home use in the EU5 markets. The specific challenge was that key feature that made the device attractive to patients had the potential to lower profits for home medical equipment resellers.
RG+A was engaged by a global device manufacturer to help determine market response to a potential new device for testing for the presence of trace hazardous drugs in hospital pharmacies and infusion areas. The client sought to determine whether to continue development of the product and in what form.
RG+A was engaged by a diagnostics manufacturer to help determine the best business approach to for a potentially disruptive prostate cancer screening product – continue development, sell the asset, or discontinue. RG+A conducted telephone-based mini-groups among key stakeholders, and incorporated the findings into a Monte Carlo model to determine the likelihood of achieving the client’s threshold for revenue success.
RG+A used Qualitative Conjoint combined with a Monte Carlo model to help a vascular device company optimize their product development investment by uncovering the right features to drive the greatest benefits to competitive response and long-term share.
One BioTech client increased market capitalization 21.2% overnight based on a RG+A pricing recommendation that they implemented.
The contraception franchise of a major pharmaceutical company was under competitive threat by a discount product coming to market within two years. RG+A was engaged to help the client understand the impact to their franchise – both inline and pipeline products – and to identify variations of the competitor’s product profile that would have the greatest impact on share.
Facing imminent generic competition for their branded respiratory product, a pharmaceutical company engaged RG+A to help them understand the complex payer stakeholder landscape and to provide guidance on key strategies to strengthen the brand’s position with payers at present and following the generic launch
RG+A’s client sought to optimize the post-launch value of their early stage respiratory asset by incorporating key payer perspectives into product strategy and trial design in support of high likelihood of reimbursement. RG+A used our Co-Creation approach to engage payers from our Health Payer Council community directly in the development of an optimal target product profile (TPP) and viable trial design to support the client’s post-launch objectives.
RG+A’s client needed to make a go/no-go decision for a Phase III clinical trial for a novel ADHD medication. It was unknown whether or not the product would get either an adult or adult and pediatric indication. RG+A used a combination of DPS® and QTM® methodologies to deliver answers to all of these major research questions along with a recommendation about how to proceed with the Phase III clinical trial.
A single DPS® study provided decision support on five key issues, ranging from forecasting market share to designing clinical trials and targeting key stakeholder segments
RG+A’s client was preparing for the launch of a product for which there was a likely launch of a competitor within the same timeframe. They identified payer contracting as critical to meeting their brand access goals and engaged RG+A to help understand the contracting process from end to end.
A qualitative conjoint study with 30 managers of out-patient oncology infusion centers identified two distinct approaches to contracting.
Using a two-element approach consisting of qualitative interviews and RG+A’s Dynamic Practice Simulation® method, RG+A was able to identify key factors impacting physician likelihood to prescribe and to recommend changes in the brand’s communications approach to boost receptivity to the product.